Changing treatment: latest news

Changing treatment resources

Changing treatment features

Changing treatment in your own words

Changing treatment news from aidsmap

More news

Changing treatment news selected from other sources

  • Viral load rebounds in 35% of people using PI/r monotherapy: results of five-year PIVOT study

    A long-term strategy study sponsored by the Medical Research Council (MRC) in the UK reported low rates of serious complications and the potential to reduce drug costs. However, more than a third of people on the PI/r monotherapy group had viral load rebound compared to only 3% of people on standard combination therapy.

    10 March 2014 | HIV i-Base
  • U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

    European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union.

    16 December 2013 | Gilead press release
  • Once-daily raltegravir for 48 weeks as maintenance therapy in Paris

    Sixty-eight of 71 people who switched to once-daily raltegravir with a viral load below 50 copies maintained virologic suppression for 48 weeks in an observational study at a Paris hospital. Virologic failure occurred in 3 people taking nucleos(t)ides with raltegravir who had a previous nucleos(t)ide failure.

    22 October 2013 | NATAP
  • TDF/FTC-to-ABC/3TC switch maintains viral suppression, eases bone markers

    A switch from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine (ABC/3TC), both with atazanavir/ritonavir, maintained viral suppression through 48 weeks in a noninferiority analysis and improved bone and kidney markers. Four people in the ABC/3TC arm (2%) and one in the TDF/FTC arm (1%) had study-defined virologic failure by week 48.

    19 September 2013 | NATAP
  • Switching From Efavirenz to Rilpivirine Combo Quells CNS Side Effects

    Swapping efavirenz-containing Atripla for rilpivirine-containing Complera (Eviplera in Europe) significantly lowered rates of central nervous system (CNS) side effects and sleep disturbances in a 40-person multicenter pilot trial.

    13 September 2013 | NATAP
  • Lessons Learned When the Labs Go Awry

    David Fawcett describes the feelings - and the lessons - when a rebound in viral load resulted in a change of his HIV medication.

    10 September 2013 |
  • Computer models predict how patients will respond to HIV drugs

    Results of a new study demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. Crucially for patients in poorer countries, the models do not require the results of expensive drug resistance tests to make their predictions. The study also showed that the models were able to identify alternative drug combinations that were predicted to work in cases where the treatment used in the clinic had failed, suggesting that their use could avoid treatment failure.

    14 March 2013 | Eurekalert Inf Dis
  • PI monotherapy for HIV — an idea whose time has passed?

    Patients who switched from suppressive triple-drug therapy to boosted protease-inhibitor monotherapy had unreasonably high rates of treatment failure.

    05 December 2012 | Journal Watch
  • Raltegravir-resistant HIV stays susceptible to dolutegravir in lab

    HIV resistant to the integrase inhibitor raltegravir and isolated from patients taking a failing raltegravir regimen remained largely susceptible to the integrase inhibitor dolutegravir in phenotypic susceptibility testing. Raltegravir-resistant virus carrying a mutation at position Q148 had more reduced susceptibility to dolutegravir than isolates with other raltegravir mutations.

    13 November 2012 | International AIDS Society
  • Pegylated interferon may maintain HIV suppression and reduce viral DNA integration

    Adding pegylated interferon alfa to antiretroviral therapy (ART) for HIV may help some people control viral replication when they interrupt treatment, according to a small study reported at this year's Conference on Retroviruses and Opportunistic Infections (CROI 2012) and published in the October 26, 2012, advance online edition of the Journal of Infectious Diseases.

    12 November 2012 |
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.